

## Disclosures

### Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Daiichi Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
MOCHIDA PHARMACEUTICAL CO., LTD.	Speaker's Bureau	Modest (< \$5,000)	Prevention
ONO PHARMACEUTICAL	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Otsuka Pharmaceutical Co.	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Takeda Pharmaceuticals, Inc	Speaker's Bureau	Modest (< \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
VOYAGER PAD	Bayer Healthcare Pharmaceuticals	
VICTORIA	Bayer Healthcare Pharmaceuticals	
GLORIA-AF	Boehringer Ingelheim Pharmaceuticals, Inc	
J-SHIFT	Ono Pharmaceutical	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 9/19/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 9/19/2022

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.